Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China
· Delayed Price · Currency is CNY 32.81
-0.91 (-2.70%)
Mar 9, 2026, 3:00 PM CST
SHA:688076 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | - | 404.39 | 162.94 | 129.11 | 115.39 | Upgrade
|
| Depreciation & Amortization | - | 209.29 | 135.55 | 99.96 | 84.77 | Upgrade
|
| Other Amortization | - | 7.73 | 4.61 | 4.72 | 4.25 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | -0.5 | -0.18 | -18.89 | -0.06 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 9.7 | 15.3 | 0.45 | 2.31 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | 1.72 | -3.16 | -19.98 | -3.22 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 20.62 | 5.11 | 5.87 | 1.65 | Upgrade
|
| Other Operating Activities | - | 58.16 | 49 | 29.63 | 15.44 | Upgrade
|
| Change in Accounts Receivable | - | -348.97 | -126.49 | -145.04 | -45.88 | Upgrade
|
| Change in Inventory | - | -243.29 | -82.58 | -111.74 | -87.63 | Upgrade
|
| Change in Accounts Payable | - | 291.17 | 180.38 | 58.34 | 75.82 | Upgrade
|
| Change in Other Net Operating Assets | - | 32.63 | 23.3 | 1.71 | 8.77 | Upgrade
|
| Operating Cash Flow | - | 400.12 | 350.21 | 29.29 | 180.75 | Upgrade
|
| Operating Cash Flow Growth | - | 14.25% | 1095.59% | -83.79% | 27.84% | Upgrade
|
| Capital Expenditures | - | -1,090 | -660.64 | -438.36 | -233.36 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 3.98 | 1.53 | 0.06 | 0.34 | Upgrade
|
| Divestitures | - | - | - | 13.12 | - | Upgrade
|
| Investment in Securities | - | -308 | -6 | -25.95 | -7 | Upgrade
|
| Other Investing Activities | - | 0.95 | 2.9 | 1.39 | 3.09 | Upgrade
|
| Investing Cash Flow | - | -1,393 | -662.21 | -449.74 | -236.93 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 242.68 | Upgrade
|
| Long-Term Debt Issued | - | 1,698 | 1,146 | 388.99 | - | Upgrade
|
| Total Debt Issued | - | 1,698 | 1,146 | 388.99 | 242.68 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -422.79 | Upgrade
|
| Long-Term Debt Repaid | - | -901.76 | -454.73 | -129.65 | -4.11 | Upgrade
|
| Total Debt Repaid | - | -901.76 | -454.73 | -129.65 | -426.91 | Upgrade
|
| Net Debt Issued (Repaid) | - | 796.43 | 691.05 | 259.34 | -184.23 | Upgrade
|
| Issuance of Common Stock | - | 22.98 | - | - | 762.63 | Upgrade
|
| Common Dividends Paid | - | -118.75 | -57.61 | -40.57 | -6.04 | Upgrade
|
| Dividends Paid | - | -118.75 | -57.61 | -40.57 | -6.04 | Upgrade
|
| Other Financing Activities | - | 99.1 | -1.54 | 18.15 | -37.47 | Upgrade
|
| Financing Cash Flow | - | 799.75 | 631.9 | 236.91 | 534.89 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 8.34 | -3.21 | -0.82 | -1.58 | Upgrade
|
| Net Cash Flow | - | -184.98 | 316.69 | -184.35 | 477.13 | Upgrade
|
| Free Cash Flow | - | -690.01 | -310.43 | -409.07 | -52.61 | Upgrade
|
| Free Cash Flow Margin | - | -42.47% | -30.04% | -62.81% | -8.17% | Upgrade
|
| Free Cash Flow Per Share | - | -2.24 | -1.03 | -1.38 | -0.20 | Upgrade
|
| Cash Income Tax Paid | - | 18.56 | 8.2 | -29.3 | -11.18 | Upgrade
|
| Levered Free Cash Flow | - | -856.88 | -374.23 | -441.9 | -133.86 | Upgrade
|
| Unlevered Free Cash Flow | - | -835.17 | -364.18 | -436.11 | -130.04 | Upgrade
|
| Change in Working Capital | - | -311 | -18.95 | -201.59 | -39.78 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.